Physician Characteristics and Knowledge of CKD Management

American Journal of Kidney Diseases

Volumn 54, Issue 2, 2009, Pages 238-247

  Israni, Rubeen K ^a   Shea, Judy A ^b   Joffe, Marshall M ^c   Feldman, Harold I ^c,d  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Renal Division   (United States)

Author keywords

Chronic kidney disease; physician knowledge; quality of care

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; PATIENT CARE; PATIENT REFERRAL; PHYSICIAN; PROTEINURIA; STRUCTURED QUESTIONNAIRE;

CHRONIC DISEASE; CLINICAL COMPETENCE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; QUESTIONNAIRES;

EID: 67650418117     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.01.258     Document Type: Article

References (33)

1. Saydah S., Eberhardt M., Rio-Burrows N., Williams D., Geiss L., and Dorsey R. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep 56 (2007) 161-165
2. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
3. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
4. Muntner P., He J., Hamm L., Loria C., and Whelton P.K. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13 (2002) 745-753
5. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
6. Jafar T.H., Stark P.C., Schmid C.H., et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60 (2001) 1131-1140
7. Kinchen K.S., Sadler J., Fink N., et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 137 (2002) 479-486
8. Ruggenenti P., Perna A., and Remuzzi G. ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12 (2001) 2832-2837
9. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
10. Coresh J., Wei G.L., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161 (2001) 1207-1216
11. Hsu C.Y., Bates D.W., Kuperman G.J., and Curhan G.C. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. Am J Hypertens 14 (2001) 1219-1225
12. Israni A., Korzelius C., Townsend R., and Mesler D. Management of chronic kidney disease in an academic primary care clinic. Am J Nephrol 23 (2003) 47-54
13. Parikh N.I., Hwang S.J., Larson M.G., Meigs J.B., Levy D., and Fox C.S. Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med 166 (2006) 1884-1891
14. Patwardhan M.B., Samsa G.P., Matchar D.B., and Haley W.E. Advanced chronic kidney disease practice patterns among nephrologists and non-nephrologists: A database analysis. Clin J Am Soc Nephrol 2 (2007) 277-283
15. Tiwari A., Tseng C.L., Kern E.F., Maney M., Miller D.R., and Pogach L. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease. Am J Manag Care 13 (2007) 73-79
16. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 suppl 1 (2002) S1-S266
17. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43 suppl 1 (2004) S1-S290
18. Gorsuch R.L. Factor Analysis. (ed 2) (1983), Erlbaum, London, England
19. Pett M.A., Lackey N.R., and Sullivan J.J. Making Sense of Factor Analysis: The Use of Factor Analysis for Instrument Development in Health Care Research (2003), Sage, Thousand Oaks, CA
20. Boulware L.E., Troll M.U., Jaar B.G., Myers D.I., and Powe N.R. Identification and referral of patients with progressive CKD: A national study. Am J Kidney Dis 48 (2006) 192-204
21. Akbari A., Swedko P.J., Clark H.D., et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program. Arch Intern Med 164 (2004) 1788-1792
22. Wyatt C., Konduri V., Eng J., and Rohatgi R. Reporting of estimated GFR in the primary care clinic. Am J Kidney Dis 49 (2007) 634-641
23. Wong T., Foote E.F., Lefavour G.S., Cody R.P., Brown C.J., and Sherman R.A. Physician knowledge and practice patterns relating to diabetic nephropathy. J Am Pharm Assoc (Wash) 39 (1999) 785-790
24. Lenz O., and Fornoni A. Chronic kidney disease care delivered by US family medicine and internal medicine trainees: Results from an online survey. BMC Med 4 (2006) 30
25. Cooke C.E., and Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J Manag Care Pharm 12 (2006) 649-655
26. Winkelmayer W.C., Fischer M.A., Schneeweiss S., Wang P.S., Levin R., and Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 46 (2005) 1080-1087
27. Cook S., Drum M.L., Kirchhoff A.C., et al. Providers' assessment of barriers to effective management of hypertension and hyperlipidemia in community health centers. J Health Care Poor Underserved 17 (2006) 70-85
28. Margolis K.L., Rolnick S.J., Fortman K.K., Maciosek M.V., Hildebrant C.L., and Grimm Jr. R.H. Self-reported hypertension treatment beliefs and practices of primary care physicians in a managed care organization. Am J Hypertens 18 (2005) 566-571
29. Ezzati M., Oza S., Danaei G., and Murray C.J. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 117 (2008) 905-914
30. Wong N.D., Lopez V.A., L'Italien G., Chen R., Kline S.E., and Franklin S.S. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 167 (2007) 2431-2436
31. Persson M., Carlberg B., Tavelin B., and Lindholm L.H. Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: Fair risk assessment but defensive treatment policy. J Hypertens 22 (2004) 65-71
32. Minutolo R., De Nicola L., Zamboli P., et al. Management of hypertension in patients with CKD: Differences between primary and tertiary care settings. Am J Kidney Dis 46 (2005) 18-25
33. Huse D.M., Roht L.H., Alpert J.S., and Hartz S.C. Physicians' knowledge, attitudes, and practice of pharmacologic treatment of hypertension. Ann Pharmacother 35 (2001) 1173-1179